141 search results for: Pathophysiology

Learn how loss of smell in CRSwNP is a key symptom for both patients and providers.

Learn about type 2 inflammation as a driver of neurosensitization and chronic itch in atopic dermatitis with this educational tool.

Learn about the significant burden that patients with COPD experience and the role of inflammatory mechanisms in this chronic, often progressive disease. 

Highlights from the ADVENT educational symposium at EADV 2024 discussing the current understanding of the science and treatment landscape in bullous pemphigoid (BP).

Join the effort to improve CRSwNP care. World Anosmia Day serves as an opportunity to raise awareness about the loss of the sense of smell. Access some of countless educational resources with ADVENT below.

In this podcast, Dr. Teri Greiling and Dr. Daniel Butler discuss the enormous burden patients with bullous pemphigoid experience and how our understanding of the disease pathophysiology may help address unmet treatment needs.

Join Christine Bangert, Mark Boguniewicz and Perla Lansang for an educational symposium on atopic dermatitis (AD) in children, exploring the diagnosis and pathophysiology of AD in children, the life-long effects of uncontrolled disease beyond the skin, and current and emerging therapies.

In this video soundbite from the EAACI 2025 symposium, Dr. Philippe Gevaert explains how biologic options for uncontrolled CRSwNP are increasing, and phase 3 studies of approved biologics show improved outcomes and decreased SCS use/surgery in patients with CRSwNP. Additionally, he explains how biologics targeting type 2 inflammatory pathophysiology potentially improve outcomes for eligible patients with co-existing CRSwNP and asthma.

The underlying pathophysiology of atopic dermatitis (AD) is driven by dysregulation of type 2 immunity that contributes to skin barrier dysfunction. AD typically develops very early in life and children with AD often develop other atopic conditions such as food allergy, asthma, and allergic rhinitis in a progression called the atopic march. Early treatment may help reduce the atopic march and other comorbidities to lessen the lifetime burden created by these diseases. There may even be a window of opportunity for disease modification.

In this educational presentation, Profs. Vibeke Backer and Sietze Reitsma cover key aspects of type 2 inflammation and its role in the pathogenesis and management of CRSwNP and practical strategies for optimizing disease control and improving patient outcomes.

Professor Lisa Beck explores the chronic and persistent burden of atopic dermatitis (AD) as well as the concept of early intervention in patients with AD.

Learn about the multifaceted burden of uncontrolled pediatric asthma on patients and their caregivers.